New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring
IRVINE, Calif., June 12 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI ), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that three new independent studies demonstrating the clinical accuracy and utility of Masimo PVI as a nonin...
Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009
Cardiovascular Safety and Potential Benefits of Exenatide to be Prospectively Assessed in Large Outcomes Trial
NEW ORLEANS, June 8 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) and Eli Lilly and Company (NYSE: LLY ) today announced results from a meta-analysis of ...
SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine
WASHINGTON, June 7 /PRNewswire/ -- BARI-2D is a useful and focused trial that builds on the body of scientific knowledge physicians use to provide the best possible care for diabetic patients with chronic stable angina and to evaluate their treatment options. The Society for Cardiovascular Angiog...
Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009
Improvements in Systolic Blood Pressure and Triglycerides Also Observed
NEW ORLEANS, June 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ), Eli Lilly and Company (NYSE: LLY ), and Alkermes, Inc. (Nasdaq: ALKS ) today announced long-term, interim results from the ...
AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA
Two-year study presented
at the American Diabetes Association's 69th Scientific Sessions shows investigational product comparable to standard insulin therapy in pulmonary function tests
NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- AFRESA(R) (insulin human [rDNA origin]) Inhalation Powder is ...
Ethicon Endo-Surgery Studies Presented at DDW Demonstrate Potential of Pure NOTES Surgery With Company's Toolbox
CINCINNATI, June 3 /PRNewswire/ -- Ethicon Endo-Surgery, Inc. today announced that multiple studies presented
at the 2009 Digestive Disease Week (DDW) demonstrate the company's novel, investigational* Toolbox enables natural orifice translumenal endoscopic surgery (NOTES) procedures without lap...
PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
Oral CCR9 Antagonist Demonstrates Clinical Efficacy with Favorable Tolerability Profile
MOUNTAIN VIEW, Calif., June 1 /PRNewswire/ -- ChemoCentryx, Inc., announced that Phase II/III clinical data from the company's PROTECT-1 (the P rospective R andomized O ral T herapy E valuation in ...
Data From Clinical Study of bioTheranostics Molecular Diagnostic Test Presented at American Society of Clinical Oncology Annual Meeting
- THEROS CancerTYPE ID(R) predicts cancer origin with 75 percent accuracy in patients whose primary cancer was 'unknown' using traditional diagnostics -
SAN DIEGO, June 1 /PRNewswire/ -- bioTheranostics, a bioMerieux company that discovers, develops and commercializes new molecular diagnostic...
Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
CHICAGO, June 1 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, presented
the results of a 5-aminosalicylic acid (5-ASA) persistency analysis entitled, "Twelve-month Persistence with 5-aminosalicylic Acid Therapy: Results from a Lar...
TNFerade(TM) Phase III Data Presented at ASCO
GAITHERSBURG, Md., June 1 /PRNewswire-FirstCall/ -- Overall survival data in locally advanced pancreatic cancer patients treated with TNFerade(TM) in GenVec's ongoing Phase III Pancreatic Cancer Clinical Trial with TNFerade(TM) (PACT) were presented
yesterday at the 45th American Society of Clinic...
Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
ORLANDO, Fla., May 30 Data from the Phase III ZODIAC study in advanced non-small cell lung cancer patients, with the investigational drug vandetanib, were presented
today at the American Society of Clinical Oncology (ASCO) meeting in Orlando. Results show that the study met its primary endpoint, d...
Results and Additional Analyses From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
SAN MATEO¿ Calif.¿ May 28 /PRNewswire/ -- Results and additional analyses from the Phase II portion of a Phase II/III clinical trial of Corthera's investigational drug relaxin for the treatment of acute heart failure will be presented
at the Heart Failure Congress, the annual meeting of the Heart ...
Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop
BUDAPEST, Hungary and EXTON, Pa., May 26 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM ) today announced the presentation of five abstracts relating to Cinryze(TM) (C1 esterase inhibitor [human]) therapy at the 6th Annual C1 Inhibitor Deficiency Workshop.
Cinryze was appr...
TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009
SAN DIEGO, May 26 /PRNewswire/ -- TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and related diseases, announced today that Phase 1 clinical results from studies of TRC105 and TRC102 in patients with advanced cancer will be presented
at the American S...
PARI Pharma's Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS
Positive Results Based on New DSCG Formulation & eFlow Technology Delivery
MUNICH and MONTEREY, Calif., May 20 /PRNewswire/ -- This week, Swiss researchers presented
positive data from an ongoing Phase II clinical study at the American Thoracic Society (ATS) International Conference that ...
Ridge Diagnostics, Inc. Clinical Data on Blood Test for Depression Presented at American Psychiatric Association Annual Meeting
SAN DIEGO, May 20 /PRNewswire/ -- Ridge Diagnostics, Inc., a neurodiagnostic company, announced that data from clinical studies for its first-in-class, proprietary blood test for Major Depressive Disorder(MDD), will be presented
during a poster session entitled Multianalyte Biomarker Blood Test...
Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents
Other Presentations Highlight Pre-clinical Work of Company's Future Pro-healing Technologies
BARCELONA, Spain, May 20 /PRNewswire/ -- OrbusNeich announced today that two year follow up data from a single center, randomized clinical study in patients at high risk of restenosis were presented
Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
- Results suggest pirfenidone may provide meaningful clinical benefit in IPF patients -
- Results of new analyses of efficacy and safety reported -
- Conference Call and Webcast at 9 p.m. EDT (6 p.m. PDT) -
SAN DIEGO, May 19 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN...
Clinical Data on Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting
INDIANAPOLIS, May 19 /PRNewswire/ -- Semafore Pharmaceuticals, Inc., a privately held cancer drug discovery and development company, today announced that it will be reporting Phase I clinical data on its vascular targeted pan-PI3K/mTORC1/2 inhibitor, SF1126, during the 2009 American Society of Cli...
Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
SEATTLE, May 15 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that data from CTI's pivotal phase III EXTEND (PIX301) trial of pixantrone in patients with advanced, relapsed aggressive non-Hodgkin's lymphoma (NHL) will be presented
at the 2009 American Soc...
Autism Studies Presented at Mid-Atlantic Research Consortium Meeting
PHILADELPHIA, May 8 /PRNewswire-USNewswire/ -- Science is largely a collaborative enterprise. Frequently researchers from various disciplines but with some common interests pool their efforts and exchange ideas, to devise new avenues of investigation. When unraveling complex conditions such as tho...
Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis
- Primary Endpoint met With a Significant Reduction in Relapse Rate
- Secondary Endpoints met Including MRI Measures, Proportion of Patients Relapse-Free and Disability Progression
- Submission for Registration of Cladribine Tablets Planned for mid-2009
SEATTLE and GENEVA, April 30 ...
New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting
Data indicated comparable efficacy and safety for extended release and immediate release formulations of pramipexole
SEATTLE, April 29 /PRNewswire/ -- New findings from two double-blind studies investigating the efficacy, safety and tolerability of pramipexole dihydrochloride tablets in an ...
Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
- Extended Median Survival by 4.1 Months and Increased 3-Year Survival by 38 Percent Compared to Placebo -
- First Active Cellular Immunotherapy for Cancer to Prolong Survival -
- Company to Host Webcast at 5:30 pm ET -
CHICAGO and SEATTLE, April 28 /PRNewswire-FirstCall/ -- Dendreo...
Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model
-Preclinical Results Further Validate Significant Anti-Tumor Potential of Fully Human Anti-PS Antibodies and Expand the Company's PS-Targeting Platform-
-Treatment with Mouse Equivalent to the Human Antibody Inhibited Tumor Growth in a Prostate Cancer Model by More than 90%-
Processed Tomato Products May Protect Against Inflammation, According to a Study Presented at the Experimental Biology Meeting
SACRAMENTO, Calif., April 21 /PRNewswire-USNewswire/ -- Tomato products may protect against inflammation. Such were the findings from a recent multi-center, randomized, controlled trial on the effects of processed tomatoes on vasodilatation and C-reactive protein in overweight and obese men and w...
Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies
- Preclinical Studies Highlight the Ability of PS-Targeting Antibodies to Reverse the Immune Suppressing Effects of Tumors by Changing the Tumor Microenvironment and Mobilizing Key Components of the Immune System -
- Studies Confirm Peregrine's PS-Targeting Antibodies Stimulate Dendritic C...
Cequent tkRNAi Technology to be Presented at the Centennial Meeting of the American Association for Cancer Research
Monday poster honored with special recognition awarded to top-rated abstracts
CAMBRIDGE, Mass., April 15 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that the company's Trans...
Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology
ANNAPOLIS, Md., March 31 /PRNewswire-FirstCall/ --PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that new mechanism of action data for Valortim(R) were presented
at the Keystone Symposia on Mol...
RenalGuard(R) Pilot Safety Clinical Trial Data to be Presented at ACC 2009
FRANKLIN, Mass., March 27 /PRNewswire-FirstCall/ -- PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that the first data from its pilot safety trial for RenalGuard(R) will be presented
in a poster ...
Results From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session
SAN MATEO¿ Calif.¿ March 23 /PRNewswire/ -- Results from the Phase II portion of a Phase II/III clinical trial of Corthera's investigational drug relaxin for the treatment of acute heart failure will be presented
at 10:30 a.m. EDT on Sunday, March 29, at the American College of Cardiology's (ACC...
Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections
BIRMINGHAM, Ala., Feb. 23 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX ) today announced that the full data set from an exploratory Phase 2 study of peramivir in patients hospitalized for influenza was presented
by the study's Principal Investigator, Dr. Michael G. Ison, Assi...
Results of NeuroThera Effectiveness and Safety Trial - 2 (NEST-2) Presented at International Stroke Conference 2009
Encouraging Safety and Efficacy Results Support Follow-on NEST-3 Trial
CARLSBAD, Calif., Feb. 20 /PRNewswire/ -- In a clinical trial sponsored by PhotoThera, Inc., transcranial laser therapy (TLT) for acute ischemic stroke within 24 hours of stroke onset demonstrated improved outcomes for pat...
Hope for 14 Million Rosacea Sufferers: Pyratine-XR(TM) Study to be Presented at South Beach Symposium
NAPA, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Senetek PLC
(OTC Bulletin Board: SNKTY), a life sciences company engaged in the
development of technologies that target the science of healthy aging,
announced today that positive study results from a clinical trial of
Pyratine-XR(TM) in patients...
Oridion Announces Significant Medical Studies Presented at STA
JERUSALEM and NEEDHAM, Massachusetts, February 2 /PRNewswire-FirstCall/
-- Oridion Systems Ltd. (SIX Swiss Exchange: ORIDN). During the recent annual
meeting of the Society for Technology in Anesthesia (STA) San Antonio, Texas,
major new findings from numerous medical research projects demonst...
Advances in Science and Treatment of Pain Presented at 25th Annual American Academy of Pain Medicine Meeting January 28 - 31, 2009
Further Understanding of Pain as a Disease Leads to Innovation in Treatment
GLENVIEW, Ill., Jan. 26 /PRNewswire/ -- The American Academy of Pain Medicine's (AAPM) 2009 Annual Meeting - its 25th Anniversary - will take place in Hawaii this week with over 200 scientific posters, presentations a...
Positive Phase II Study of Pacira's EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
PARSIPPANY, N.J., Dec. 14 /PRNewswire/ -- A Phase II trial of a single
intraoperative administration of EXPAREL (DepoBupivacaine) resulted in
significantly reduced pain with activity in the first 8 to 24 hours following
surgery, when pain is generally greatest, compared to conventional treatment.
Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium
SAN DIEGO, Dec. 14 /PRNewswire/ -- bioTheranostics, a bioMerieux company
that discovers, develops and commercializes new molecular diagnostic tests in
oncology, reported today findings from three studies using the company's
molecular breast cancer assay to predict risk of disease recurrence in
Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL
Data Showed Campath May Lead to Overall Survival in Patients with Poor Prognostic Factors
SAN FRANCISCO, Dec. 9 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. today announced results from three studies showing that treatment with Campath(R) (alemtuzumab) showed activity in high-ris...
Dacogen(R) (decitabine for injection) Data Presented on a Phase II Clinical Trial in Elderly Patients with Acute Myeloid Leukemia (AML)
Response Observed Across All Subtypes of AML, Including Those with Poorest Prognoses
SAN FRANCISCO, Dec. 8 /PRNewswire/ -- Eisai Corporation of North America today announced data from a Phase II trial evaluating a five-day dosing regimen of Dacogen(R) (decitabine for injection) in acute m...